TY  - JOUR

T1  - Validity of proportional hazards (PH) Weibull models for analyzing progression free survival (PFS) and overall survival (OS) in patients with trastuzumab (TZ)-refractory ERBB2+(HER2+) metastatic breast cancer (MBC) receiving lapatinib plus capecitabine (L+C) versus capecitabine only (C-only)

JO  - VALUE HEALTH

PY  - 2008/05/01

AU  - Sofrygin O

AU  - Delea T

AU  - Tappenden P

AU  - Karnon J

AU  - Amonkar MM

AU  - Walker M

ED  - 

VL  - 11

IS  - 3

SP  - A57

EP  - A57

Y2  - 2024/12/21

ER  -